Publication:
Quantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland.

cris.virtual.author-orcid0000-0002-5230-6760
cris.virtualsource.author-orcid6c0e9ae6-71dc-487a-bfe2-5908d1078b9a
datacite.rightsopen.access
dc.contributor.authorChen, Chaoran
dc.contributor.authorNadeau, Sarah Ann
dc.contributor.authorTopolsky, Ivan
dc.contributor.authorManceau, Marc
dc.contributor.authorHuisman, Jana S
dc.contributor.authorJablonski, Kim Philipp
dc.contributor.authorFuhrmann, Lara
dc.contributor.authorDreifuss, David
dc.contributor.authorJahn, Katharina
dc.contributor.authorBeckmann, Christiane
dc.contributor.authorRedondo, Maurice
dc.contributor.authorNoppen, Christoph
dc.contributor.authorRisch, Lorenz
dc.contributor.authorRisch, Martin
dc.contributor.authorWohlwend, Nadia
dc.contributor.authorKas, Sinem
dc.contributor.authorBodmer, Thomas
dc.contributor.authorRoloff, Tim
dc.contributor.authorStange, Madlen
dc.contributor.authorEgli, Adrian
dc.contributor.authorEckerle, Isabella
dc.contributor.authorKaiser, Laurent
dc.contributor.authorDenes, Rebecca
dc.contributor.authorFeldkamp, Mirjam
dc.contributor.authorNissen, Ina
dc.contributor.authorSantacroce, Natascha
dc.contributor.authorBurcklen, Elodie
dc.contributor.authorAquino, Catharine
dc.contributor.authorde Gouvea, Andreia Cabral
dc.contributor.authorMoccia, Maria Domenica
dc.contributor.authorGrüter, Simon
dc.contributor.authorSykes, Timothy
dc.contributor.authorOpitz, Lennart
dc.contributor.authorWhite, Griffin
dc.contributor.authorNeff, Laura
dc.contributor.authorPopovic, Doris
dc.contributor.authorPatrignani, Andrea
dc.contributor.authorTracy, Jay
dc.contributor.authorSchlapbach, Ralph
dc.contributor.authorDermitzakis, Emmanouil T
dc.contributor.authorHarshman, Keith
dc.contributor.authorXenarios, Ioannis
dc.contributor.authorPegeot, Henri
dc.contributor.authorCerutti, Lorenzo
dc.contributor.authorPenet, Deborah
dc.contributor.authorBlin, Anthony
dc.contributor.authorElies, Melyssa
dc.contributor.authorAlthaus, Christian
dc.contributor.authorBeisel, Christian
dc.contributor.authorBeerenwinkel, Niko
dc.contributor.authorAckermann, Martin
dc.contributor.authorStadler, Tanja
dc.date.accessioned2024-09-02T17:54:45Z
dc.date.available2024-09-02T17:54:45Z
dc.date.issued2021-12
dc.description.abstractBACKGROUND In December 2020, the United Kingdom (UK) reported a SARS-CoV-2 Variant of Concern (VoC) which is now named B.1.1.7. Based on initial data from the UK and later data from other countries, this variant was estimated to have a transmission fitness advantage of around 40-80 % (Volz et al., 2021; Leung et al., 2021; Davies et al., 2021). AIM This study aims to estimate the transmission fitness advantage and the effective reproductive number of B.1.1.7 through time based on data from Switzerland. METHODS We generated whole genome sequences from 11.8 % of all confirmed SARS-CoV-2 cases in Switzerland between 14 December 2020 and 11 March 2021. Based on these data, we determine the daily frequency of the B.1.1.7 variant and quantify the variant's transmission fitness advantage on a national and a regional scale. RESULTS We estimate B.1.1.7 had a transmission fitness advantage of 43-52 % compared to the other variants circulating in Switzerland during the study period. Further, we estimate B.1.1.7 had a reproductive number above 1 from 01 January 2021 until the end of the study period, compared to below 1 for the other variants. Specifically, we estimate the reproductive number for B.1.1.7 was 1.24 [1.07-1.41] from 01 January until 17 January 2021 and 1.18 [1.06-1.30] from 18 January until 01 March 2021 based on the whole genome sequencing data. From 10 March to 16 March 2021, once B.1.1.7 was dominant, we estimate the reproductive number was 1.14 [1.00-1.26] based on all confirmed cases. For reference, Switzerland applied more non-pharmaceutical interventions to combat SARS-CoV-2 on 18 January 2021 and lifted some measures again on 01 March 2021. CONCLUSION The observed increase in B.1.1.7 frequency in Switzerland during the study period is as expected based on observations in the UK. In absolute numbers, B.1.1.7 increased exponentially with an estimated doubling time of around 2-3.5 weeks. To monitor the ongoing spread of B.1.1.7, our plots are available online.
dc.description.numberOfPages8
dc.description.sponsorshipInstitut für Sozial- und Präventivmedizin (ISPM)
dc.identifier.doi10.48350/159353
dc.identifier.pmid34488035
dc.identifier.publisherDOI10.1016/j.epidem.2021.100480
dc.identifier.urihttps://boris-portal.unibe.ch/handle/20.500.12422/43733
dc.language.isoen
dc.publisherElsevier
dc.relation.ispartofEpidemics
dc.relation.issn1755-4365
dc.relation.organizationInstitute of Social and Preventive Medicine
dc.subjectB.1.1.7 COVID-19 Pandemic SARS-CoV-2 Transmission advantage
dc.subject.ddc600 - Technology::610 - Medicine & health
dc.subject.ddc300 - Social sciences, sociology & anthropology::360 - Social problems & social services
dc.titleQuantification of the spread of SARS-CoV-2 variant B.1.1.7 in Switzerland.
dc.typearticle
dspace.entity.typePublication
oaire.citation.startPage100480
oaire.citation.volume37
oairecerif.author.affiliationInstitut für Sozial- und Präventivmedizin (ISPM)
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.contributor.rolecreator
unibe.date.licenseChanged2021-09-17 18:45:09
unibe.description.ispublishedpub
unibe.eprints.legacyId159353
unibe.journal.abbrevTitleEpidemics
unibe.refereedtrue
unibe.subtype.articlejournal

Files

Original bundle
Now showing 1 - 1 of 1
Name:
Chen_Epidemics_2021.pdf
Size:
3.34 MB
Format:
Adobe Portable Document Format
License:
https://creativecommons.org/licenses/by-nc-nd/4.0
Content:
published

Collections